

Qian Xie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9195122/qian-xie-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

622
citations

14
h-index

23
g-index

23
ext. papers

752
ext. citations

7.9
avg, IF

3.9
L-index

#	Paper	IF	Citations
22	Receptor tyrosine kinases as druggable targets in glioblastoma: Do signaling pathways matter?. <i>Neuro-Oncology Advances</i> , 2021 , 3, vdab133	0.9	3
21	DSTYK Promotes Metastasis and Chemoresistance EMT in Colorectal Cancer. <i>Frontiers in Pharmacology</i> , 2020 , 11, 1250	5.6	7
20	Overexpression of HGF/MET axis along with p53 inhibition induces de novo glioma formation in mice. <i>Neuro-Oncology Advances</i> , 2020 , 2, vdaa067	0.9	4
19	-Mediated Immunity and Signaling Transduction in Gastric Cancer. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	22
18	Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. <i>Journal of Translational Medicine</i> , 2020 , 18, 428	8.5	27
17	Insufficiency of DNA repair enzyme ATM promotes naive CD4 T-cell loss in chronic hepatitis C virus infection. <i>Cell Discovery</i> , 2018 , 4, 16	22.3	26
16	Met Activation and Carcinogenesis. <i>Current Human Cell Research and Applications</i> , 2018 , 129-154	0.1	2
15	The HGF/MET Signaling and Therapeutics in Cancer. <i>Current Human Cell Research and Applications</i> , 2018 , 155-181	0.1	4
14	Phosphorothioate-Modified AP613-1 Specifically Targets GPC3 when Used for Hepatocellular Carcinoma Cell Imaging. <i>Molecular Therapy - Nucleic Acids</i> , 2018 , 13, 376-386	10.7	17
13	HCV-associated exosomes promote myeloid-derived suppressor cell expansion via inhibiting miR-124 to regulate T follicular cell differentiation and function. <i>Cell Discovery</i> , 2018 , 4, 51	22.3	19
12	Inhibition of TRF2 accelerates telomere attrition and DNA damage in naive CD4 T cells during HCV infection. <i>Cell Death and Disease</i> , 2018 , 9, 900	9.8	14
11	Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. <i>Journal of Translational Medicine</i> , 2018 , 16, 253	8.5	9
10	Near infrared fluorescent imaging of brain tumor with IR780 dye incorporated phospholipid nanoparticles. <i>Journal of Translational Medicine</i> , 2017 , 15, 18	8.5	55
9	Discovery of a highly potent glucocorticoid for asthma treatment. <i>Cell Discovery</i> , 2015 , 1,	22.3	7
8	Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. <i>Journal of Translational Medicine</i> , 2015 , 13, 306	8.5	15
7	Targeting adaptive glioblastoma: an overview of proliferation and invasion. <i>Neuro-Oncology</i> , 2014 , 16, 1575-84	1	165
6	Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. <i>Genes and Cancer</i> , 2013 , 4, 247-60	2.9	27

5	Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 570-5	11.5	96
4	RTK inhibition: looking for the right pathways toward a miracle. <i>Future Oncology</i> , 2012 , 8, 1397-400	3.6	5
3	Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 4105-10	11.5	14
2	Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma. <i>Molecular Cancer Therapeutics</i> , 2009 , 8, 2803-10	6.1	36
1	A highly invasive human glioblastoma pre-clinical model for testing therapeutics. <i>Journal of Translational Medicine</i> , 2008 , 6, 77	8.5	47